Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
7.43
-0.28 (-3.63%)
At close: Nov 7, 2025, 4:00 PM EST
7.54
+0.11 (1.48%)
After-hours: Nov 7, 2025, 7:41 PM EST
Xeris Biopharma Holdings Revenue
Xeris Biopharma Holdings had revenue of $74.38M in the quarter ending September 30, 2025, with 37.06% growth. This brings the company's revenue in the last twelve months to $266.14M, up 42.05% year-over-year. In the year 2024, Xeris Biopharma Holdings had annual revenue of $203.07M with 23.89% growth.
Revenue (ttm)
$266.14M
Revenue Growth
+42.05%
P/S Ratio
4.36
Revenue / Employee
$675,475
Employees
394
Market Cap
1.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 203.07M | 39.16M | 23.89% |
| Dec 31, 2023 | 163.91M | 53.67M | 48.68% |
| Dec 31, 2022 | 110.25M | 60.66M | 122.32% |
| Dec 31, 2021 | 49.59M | 29.16M | 142.67% |
| Dec 31, 2020 | 20.44M | 17.71M | 650.73% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
XERS News
- 3 days ago - Xeris Biopharma Holdings, Inc. (XERS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025 - Business Wire
- 17 days ago - Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025 - Business Wire
- 5 weeks ago - Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Xeris In Recorlev-Fuelled Growth: Why I Choose To Buy - Seeking Alpha
- 2 months ago - Xeris Announces Orange Book Listing of U.S. Patent for Recorlev® - Business Wire
- 3 months ago - Xeris Biopharma Holdings, Inc. (XERS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance - Business Wire